Amneal Pharmaceuticals Inc
For the period ended Dec 31, 2024. Filed Feb 28, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 28, 2025
AMRX$21.38+0.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
Consolidated Statements of Cash Flows
| Years Ended December 31, | |||
|---|---|---|---|
| 2024 | 2023 | 2022 | |
| Cash flows from operating activities: | |||
| Net loss | $(73,876) | $(48,722) | $(254,789) |
| Adjustments to reconcile net loss to net cash provided by operating activities: | |||
| Depreciation and amortization | 236,191 | 229,400 | 240,175 |
| Unrealized foreign currency loss (gain) | 7,191 | (768) | 15,190 |
| Amortization of debt issuance costs and discount | 29,097 | 11,548 | 8,595 |
| Reclassification of cash flow hedge | (26,205) | (3,366) | — |
| Loss on refinancing | — | 40,805 | 291 |
| Intangible asset impairment charges | 920 | 66,932 | 24,081 |
| Change in fair value of contingent consideration | (930) | (14,497) | 731 |
| Stock-based compensation | 27,768 | 26,822 | 31,847 |
| Inventory provision | 96,558 | 74,686 | 51,096 |
| Insurance recoveries for property and equipment losses | — | — | (1,000) |
| Other operating charges and credits, net | 2,453 | 9,923 | 8,828 |
| Changes in assets and liabilities: | |||
| Trade accounts receivable, net | (162,637) | 126,289 | (79,717) |
| Inventories | (130,530) | (126,182) | (102,396) |
| Prepaid expenses, other current assets and other assets | (959) | 37,814 | 9,882 |
| Related party receivables | 482 | (490) | 646 |
| Accounts payable, accrued expenses and other liabilities | 235,135 | (94,446) | 109,568 |
| Related party payables | 54,441 | 9,829 | 2,072 |
| Net cash provided by operating activities | 295,099 | 345,577 | 65,100 |
| Cash flows from investing activities: | |||
| Purchases of property, plant and equipment | (51,924) | (43,216) | (46,407) |
| Acquisition of intangible assets | (14,650) | (22,388) | (41,800) |
| Deposits for future acquisition of property, plant, and equipment | (8,416) | (3,585) | (2,388) |
| Acquisitions of business | — | — | (84,714) |
| Proceeds from insurance recoveries for property and equipment losses | — | — | 1,000 |
| Proceeds from sale of subsidiary | 11,994 | — | — |
| Net cash used in investing activities | (62,996) | (69,189) | (174,309) |
| Cash flows from financing activities: | |||
| Payments of deferred financing, refinancing costs and debt extinguishment costs | (71) | (162,415) | (1,663) |
| Payments of principal on debt, revolving credit facility, financing leases and other | (188,918) | (414,080) | (123,272) |
| Proceeds from issuance of debt | — | 217,732 | — |
| Borrowings on revolving credit facility | 48,000 | 219,000 | 85,000 |
| Proceeds from exercise of stock options | 1,154 | 451 | 662 |
| Employee payroll tax withholding on restricted stock unit vesting | (7,952) | (2,378) | (3,571) |
| Payments of deferred consideration for acquisitions - related party | — | — | (44,498) |
| Acquisition of redeemable non-controlling interests | — | — | (1,722) |
| Tax distributions to non-controlling interest | (19,804) | (70,883) | (17,556) |
| Repayment of related party note | (44,200) | — | — |
| Net cash used in financing activities | (211,791) | (212,573) | (106,620) |
| Effect of foreign exchange rate on cash | (999) | 65 | (5,683) |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | 19,313 | 63,880 | (221,512) |
| Cash, cash equivalents, and restricted cash - beginning of period | 99,107 | 35,227 | 256,739 |
| Cash, cash equivalents, and restricted cash - end of period | $118,420 | $99,107 | $35,227 |
| Cash and cash equivalents - end of period | $110,552 | $91,542 | $25,976 |
| Restricted cash - end of period | 7,868 | 7,565 | 9,251 |
| Cash, cash equivalents, and restricted cash - end of period | $118,420 | $99,107 | $35,227 |
Consolidated Statements of Cash Flows (continued)
| Years Ended December 31, | |||
|---|---|---|---|
| 2024 | 2023 | 2022 | |
| Supplemental disclosure of cash flow information: | |||
| Cash paid for interest | $263,518 | $192,806 | $142,722 |
| Cash paid, net for income taxes | $15,220 | $2,496 | $12,649 |
| Supplemental disclosure of non-cash investing and financing activity: | |||
| Contingent consideration for acquisition | $— | $— | $8,796 |
| Payable for acquisition of product rights and licenses | $3,900 | $2,100 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.